FRX: A SPAC, Re-bought in at 11.10

Those bast@rds. LOL. Thanks.

Thanks for the insight. Translation for us mortals: Things will be in the shitter for quite some time with mid-caps?

Yeah, sounds sketchy.

I see a symbol NEEB at $25x$175. Is that the one? And does this mean they'll give you $2,120 for your 1 share?

Nice.

Sweet. Something told me late yesterday to dump another hold of mine at a $2,000 loss and buy another 1,000 ATOM with the funds. Sometimes I actually make the right call.

:) We were in need of some good news.

The TFSA sounds great.

Been reading about those damn bond thingies.

Same. Although I wish I had paced myself at buffet this week.

That's what I was told just now on a chat session with Schwab. It took almost an hour, mostly waiting for the first person, then waiting for the second person, then: "It may take a week to get information back from the issuer." Luckily I was on the computer anyway. They offered to "call me back", but I said, "No, I'll wait". LOL

Yesterday my Schwab account indicated the split with a CUSIP # but no symbol. It still showed one share. Today there is no share, and I see no transaction crediting my account for cash, but it shows -1 share. My son used TD and said his was gone yesterday. I'll keep you updated. It's Friday, happy hour starts in 8 hours.

$CLAD - The Case for $240

This company was founded as a Nevada corporation in late 2010 as Hazlo! Technologies, Inc. On 2/11/2011, the SEC declared effective a fully-registered, direct public offering of 1,250,000 shares at a price of $0.02. All of the shares were fully subscribed for a total of $25,000 by approximately 35 investors. The shares were delivered to each subscriber in certificate form. Most, of the certificates were deposited into individual brokerage accounts. The company’s charter authorized up to 75,000,000 share. At inception the company’s two founders were issued a total of 5,200,000 restricted shares. The stock traded on the OTCBB as HAZN.

On 9/30/2011, via Form 8-K, the company reported its two founders sold 4,700,000 of their restricted shares to a resident of China. The company changed its name to China Liaoning Dingxu Ecological Agriculture Development, Inc. and trades under the symbol CLAD. Between 2011 and 2015 the company was involved in agriculture, primarily growing mushrooms in China. Yearly revenues reported in 2012 were $8.6 million (Form 10-K filed 5/15/2013), in 2013 revenue reached $12.6 million (Form 10-K filed 4/15/2014), and in 2014 revenue reached $13.2 million (Form 10-K filed 4/15/2015).

In 2015 revenue declined significantly, and the company stopped reporting. The company was virtually dead having no activity, between December 2015 and September 2018. In late 2018, via a Nevada court order, control of the company was passed to new management based in southern California.

The key to this stock being a loaded rocket is twofold. First, when CLAD’s business met its rapid demise in 2015, for reasons still unknown, management executed two, back-to-back reverse stock splits. The first was on 10/20/14 at a conversion of 1:20, and the second occurred only seven months later on 5/20/15 at a conversion rate of 1:15. This action made absolutely no sense for a company which still had millions of dollars in annual revenue. But the second and more compelling reason this stock is poised to launch is there are now only 4,166 tradable shares on the open market.

There is absolutely no indication that any current or former restricted shares have been declared unrestricted by the company, its transfer agent, or any individual. Even Rule 144 shares must be given the appropriate blessings before being accepted by a brokerage and deposited for trading. CLAD’s trading history confirms that the only available market shares since the original IPO are in fact the shares offered in the original S-1 registration, which totaled 1,250,000. The subsequent reverse splits of 1:20 and 1:15 reduced those shares down to a mere 4,166 shares. That’s why this non-current, OTC, nothing-more-than-a-shell, company has a current bid of $10 and has traded in the $10 - $19 range over the last two years with virtually no volume.

As of late the new management has made a few filings with the SEC. It’s still unclear what the direction will be, but this company is not dead and neither is the stock. The current market cap from Yahoo Finance is $23.5 million. This is based on old information and nowhere nearly describes the company’s true stock structure as it stands today, particularly regarding the number of free-trading shares. Even at a conservative $1 million company value, owning all of the free-trading shares would theoretically cost $240/share. Thin to win.

$CLAD - The Case for $240

This company was founded as a Nevada corporation in late 2010 as Hazlo! Technologies, Inc. On 2/11/2011, the SEC declared effective a fully-registered, direct public offering of 1,250,000 shares at a price of $0.02. All of the shares were fully subscribed for a total of $25,000 by approximately 35 investors. The shares were delivered to each subscriber in certificate form. Most, of the certificates were deposited into individual brokerage accounts. The company’s charter authorized up to 75,000,000 share. At inception the company’s two founders were issued a total of 5,200,000 restricted shares. The stock traded on the OTCBB as HAZN.

On 9/30/2011, via Form 8-K, the company reported its two founders sold 4,700,000 of their restricted shares to a resident of China. The company changed its name to China Liaoning Dingxu Ecological Agriculture Development, Inc. and trades under the symbol CLAD. Between 2011 and 2015 the company was involved in agriculture, primarily growing mushrooms in China. Yearly revenues reported in 2012 were $8.6 million (Form 10-K filed 5/15/2013), in 2013 revenue reached $12.6 million (Form 10-K filed 4/15/2014), and in 2014 revenue reached $13.2 million (Form 10-K filed 4/15/2015).

In 2015 revenue declined significantly, and the company stopped reporting. The company was virtually dead having no activity, between December 2015 and September 2018. In late 2018, via a Nevada court order, control of the company was passed to new management based in southern California.

The key to this stock being a loaded rocket is twofold. First, when CLAD’s business met its rapid demise in 2015, for reasons still unknown, management executed two, back-to-back reverse stock splits. The first was on 10/20/14 at a conversion of 1:20, and the second occurred only seven months later on 5/20/15 at a conversion rate of 1:15. This action made absolutely no sense for a company which still had millions of dollars in annual revenue. But the second and more compelling reason this stock is poised to launch is there are now only 4,166 tradable shares on the open market.

There is absolutely no indication that any current or former restricted shares have been declared unrestricted by the company, its transfer agent, or any individual. Even Rule 144 shares must be given the appropriate blessings before being accepted by a brokerage and deposited for trading. CLAD’s trading history confirms that the only available market shares since the original IPO are in fact the shares offered in the original S-1 registration, which totaled 1,250,000. The subsequent reverse splits of 1:20 and 1:15 reduced those shares down to a mere 4,166 shares. That’s why this non-current, OTC, nothing-more-than-a-shell, company has a current bid of $10 and has traded in the $10 - $19 range over the last two years with virtually no volume.

As of late the new management has made a few filings with the SEC. It’s still unclear what the direction will be, but this company is not dead and neither is the stock. The current market cap from Yahoo Finance is $23.5 million. This is based on old information and nowhere nearly describes the company’s true stock structure as it stands today, particularly regarding the number of free-trading shares. Even at a conservative $1 million company value, owning all of the free-trading shares would theoretically cost $240/share. Thin to win.

Got one at 3.90. Must be catching on thought, now 3.90 x 4.00. LOL

Thanks for the heads up :)

Nice call.

LOL. Awesome.

Added more pre-market at 4.56 average.

Thanks.

NBY 1.47: Not sure I get this one. It's like a yo-yo.

The share price being up doesn't hurt that argument too.

Does that mean the partnership was made, or that it's no longer a milestone?

I agree.

OBSV up $1.00 to $5.00. Nice day.

SEC to the rescue! https://finance.yahoo.com/news/u-securities-regulator-suspends-trading-155017582.html

U.S. securities regulator suspends trading in three more 'meme stocks'

FILE PHOTO: The U.S. Securities and Exchange Commission logo adorns an office door
Fri, February 19, 2021, 8:50 AM
WASHINGTON (Reuters) - The U.S. Securities and Exchange Commission on Friday suspended trading in more securities that have seen jumps in both prices and trading volumes since late January amid social media interest.

The SEC temporarily suspended trading of Marathon Group Corp, Affinity Beverage Group Inc, and Sylios Corp beginning on Friday and ending on March 4, the SEC said in statements published on its website.

The suspensions are the latest effort by the SEC to address soaring retail investor interest driven by conversation on social media platforms, most notably seen in a surge and subsequent plunge in share prices of GameStop Corp. Last week, the regulator suspended trading in a defunct stock.

- ADVERTISEMENT -

Volatile trading in so-called "meme stocks," assets which draw sudden interest from retail investors amid discussion on social media platforms, has left both hedge funds and retail investors nursing steep losses in recent weeks. The market tumult has drawn the scrutiny of federal and state regulators as well as U.S. lawmakers, who on Thursday grilled executives from online broker Robinhood, market maker Citadel Securities and hedge funds.

In each of three separate statements detailing Friday's trading suspensions, the SEC said "certain social media accounts may be engaged in a coordinated attempt to artificially influence" share prices.

The SEC has been looking at the actions of any and all participants involved in the recent trading. Potential misconduct the SEC is probing, according to its acting chair, includes: market manipulation; whether retail brokers breached fair access rules by restricting buying; the role of hedge funds with short positions in the companies, including whether there was enough data and transparency around their bets; and whether the companies took advantage of the rally to raise funds.

All three securities suspended on Friday saw sudden increases in their share prices and volumes in the absence of any publicly available news, the regulator said. The SEC further cautioned brokers and other dealers to make sure they have complied with investor protection rules when trading resumes.

(Reporting by Chris Prentice; editing by Jonathan Oatis)

OBSV up 13%

FRX 16.36 (up 35%)

First time following my son's pick: I bought some FRX (spac) yesterday at 11.50. It's looking good so far; 14.00 pre-market. Let's see how the young man does. I'm hoping he kills it. :) Just like when a son/daughter first beats you in sports like golf or tennis, it's actually a very amazing and proud moment.

Next try to get ink. LOL

LOL. For your sake I hope so.

Hit $32. Nice call, although I missed it.

I'm not sure that any analyst were projecting. I have to assume the current customer agreement didn't result in any revenue as of December 31. So the loss was based completely on expenses. The 8K doesn't show much, but it does show the increase in cash from the ATM offer.

Definitely.

OBSV news:

Nothing financial, but at least it's an update:

https://finance.yahoo.com/news/obseva-provides-business-outlook-2021-060000341.html

GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021.

“We made significant progress across all aspects of the company in 2020, most significantly preparing Yselty® for uterine fibroids for regulatory approval with a filed and validated European marketing authorization application and an upcoming planned new drug application in the US,” said Brian O’Callaghan, CEO of ObsEva. “Meanwhile our other pipeline programs have continued to advance through development as evidenced by the recent exciting topline results from the PROLONG Phase 2a proof-of concept study of ebopiprant which, to our knowledge, is the only candidate drug in active development that has the potential to delay delivery in women with spontaneous preterm labor.”

“While we remain committed to advancing our clinical development programs in women’s health, we are equally excited about our potential to extend into new indications that address important unmet needs in other therapeutic areas,” continued Mr. O’Callaghan. “As an example, we believe that linzagolix in combination with estrogen could potentially challenge the current standard of care as the best-in-class oral GnRH antagonist for the treatment of advanced prostate cancer. Recent M&A and partnering activity in the women’s reproductive health and prostate cancer landscape underscores the potential of these currently underserved patient populations as well as the importance of retaining, rather than relinquishing, the inherent value of our assets. As we approach multiple catalysts in 2021, we will continue to seek opportunities and partnerships that preserve our control and maximize the value of our pipeline candidates.”

Key 2021 Objectives

Yselty® for uterine fibroids: NDA submission (Q2:21); MAA approval (Q4:21)

Yselty® for endometriosis: Phase 3 EDELWEISS 3 primary endpoint readout (Q4:21)

Ebopiprant for treatment of preterm labor: Phase 2b dose ranging study initiation in EU/Asia (Q4:21)

Clinical Development Details

Yselty®for Uterine Fibroids

ObsEva is developing Yselty®, an oral GnRH receptor antagonist with the potential to treat more women thanks to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) recent validation of the marketing authorization application (MAA), a major milestone toward making Yselty® available in the E.U., the Company will continue to work closely with the EMA to achieve marketing approval, projected in Q4:2021.

The second key objective for 2021 will be to submit a U.S. New Drug Application (NDA), projected in Q2:2021, that will include the Week 76 post-treatment follow-up results from the Phase 3 PRIMROSE 1 (US only; n=574) and PRIMROSE 2 (Europe and US; n=535) clinical studies. In both studies, patients with heavy menstrual bleeding (HMB) associated with uterine fibroids were administered Yselty doses of 100 mg or 200 mg, with and without hormonal add-back-therapy (ABT; 1 mg estradiol(E2)/0.5 mg norethisterone acetate (NETA) or placebo. Additional information about these studies can be found here.

“Uterine fibroids impact an estimated 9 million women in the U.S. However, as the medical needs of each woman vary, we need more individualized treatment options,” said Ayman Al-Hendy, M.D., Ph.D., Distinguished Professor of Obstetrics and Gynecology at the University of Chicago Division of the Biological Sciences. “Of the millions of women with symptomatic uterine fibroids, the majority are African American, a population with higher risk of contraindications to hormonal add-back-therapy (ABT). According to the CDC, approximately 57% of non-Hispanic African American women have obesity, which is specified in oral GnRH antagonist labeling as a risk factor for venous thromboembolism when used with add-back therapy for treatment of fibroids. In addition, when preparing for surgical intervention in women with the most severe fibroids, there is often a need for rapid uterine and fibroid volume reduction, which is best achieved using short-term high-dose treatment without ABT. The PRIMROSE studies demonstrated the potential of Yselty®’s unique non-ABT options (100 mg and 200 mg without ABT) to address these needs. Furthermore, the strong results on the full suppression dose (200 mg) with ABT showed that Yselty® could potentially offer best-in-class efficacy. ObsEva’s dedication to addressing the unique needs of the diverse uterine fibroids population is welcomed and encouraging.”

Yselty®for Endometriosis

The EDELWEISS 3 trial in the EU is progressing as planned, with primary endpoint data expected in Q4: 2021. The ongoing Phase 3 EDELWEISS 3 study (Europe and US) was designed to enroll approximately 450 patients with endometriosis-associated pain, with a co-primary endpoint of response on both dysmenorrhea (menstrual pain) and non-menstrual pelvic pain. The study includes a 75 mg once-daily dose without hormonal ABT, and a 200 mg once-daily dose in combination with hormonal ABT (1 mg E2 / 0.5mg NETA). Subjects who completed the initial six-month treatment period will have the option to enter a six-month treatment extension. Additional information about this study can be found here.

As previously announced, the EDELWEISS 2 (US-only) study was recently discontinued due to challenges with screening and enrollment. ObsEva remains strongly committed to developing linzagolix for endometriosis, for which better long-term treatments are still needed. The Company plans to conduct a new Phase 3 endometriosis study with a number of design and operational adjustments to facilitate faster enrollment, with a goal to maintain the original MAA and NDA filing timelines for this important indication.

Ebopiprant (OBE022) for Treatment of Preterm Labor

A key objective for 2021 will be to initiate the Phase 2b program, which will build on the recently announced positive topline data from the PROLONG Phase 2a proof-of-concept study by initiating a late-stage clinical development program. Based on the unmet need, ebopiprant’s innovative mechanism of action and positive topline data regarding early clinical efficacy and safety in pregnant women with spontaneous preterm labor, and with no other known compound under development for this indication, the Company plans to discuss with European regulators a possible accelerated registration program based on a Phase 2b/3 adaptively designed trial. ObsEva is also engaging with key opinion leaders and plan to meet with the FDA in 1H2021 to discuss the development program in the US.

As previously described, delaying delivery by at least 48 hours in women with active preterm labor is critical for new treatments, as it allows for the maximum effect of corticosteroids administered to the mother for neonatal lung maturation and buys time for the mother to be transferred to a hospital with neonatal intensive care facilities with the expertise to manage the baby in case preterm delivery occurs.

In the PROLONG study, ebopiprant plus atosiban substantially reduced delivery at 48 hours after initiation of dosing by 43% compared to atosiban alone, with 12.5% of women (including women with twin gestations) receiving ebopiprant plus atosiban delivering within 48 hours of starting treatment, compared to 21.8% receiving atosiban alone (OR 90% CI: 0.52 (0.22, 1.23)). In singleton pregnancies, 12.5% of women receiving ebopiprant plus atosiban delivered within 48 hours compared to 26.8% receiving atosiban only (OR 90% CI: 0.39 (0.15, 1.04)). A modest overall effect on delivery at seven days was observed in singletons; however, there was a more pronounced effect in 24-to-30-week gestations, with 23.8% versus 14.3% of women delivering within 7 days in the atosiban alone and ebopiprant plus atosiban arms, respectively (OR 90% CI: 0.53 (0.14, 2.01)). The incidence of maternal, fetal, and neonatal adverse events was comparable between the ebopiprant group and placebo groups. Additional information about this study can be found here.

“Preterm birth rates are on the rise, yet there is no available FDA-approved treatment for preterm labor in the US. Women continue to face treatment options with limited efficacy or restrictive safety issues, and in this context the results from the Phase 2 ObsEva PROLONG study are very encouraging,” said George Saade, M.D., Professor of Obstetrics and Gynecology, Director of the Maternal-Fetal Medicine Division, as well as the Chief of Obstetrics at the University of Texas Medical Branch in Galveston. “The recently announced positive Phase 2a data demonstrated ebopiprant’s ability to reduce premature delivery within the critical timepoint of 48 hours, while potentially avoiding the serious maternal and fetal side effects associated with non-specific prostaglandin synthesis inhibitors and other medications currently used in women with preterm labor. I commend the company for taking a leadership role in addressing this longstanding serious unmet need.”

Nolasiban for In Vitro Fertilization

ObsEva is also developing nolasiban, an oral oxytocin receptor antagonist, to improve live birth rates in women undergoing in vitro fertilization. Additional information about this study can be found here.

Business Update and Financial Guidance

The Company plans to report its fourth quarter and full-year 2020 financial results in March.

David Renas, CFO of ObsEva, commented, “Since joining ObsEva, I can confirm that our team has been highly focused on maximizing the value of the company’s existing portfolio, including leveraging external assistance and securing new sources of funding, both equity and non-dilutive. Though our upcoming development and commercialization initiatives will require a variety of external support and financial resources, we are optimistic that the company’s unique product pipeline and a high level of talent will present a winning combination as we focus on this year’s objectives and beyond.”

About Yselty®

Yselty® (linzagolix, previously known as OBE2109) is a novel, oral, once daily, GnRH receptor antagonist with a potentially best-in-class profile. Yselty is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed Yselty from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Yselty® is a registered trademark owned by Kissei for use by ObsEva. Yselty® is not yet approved for use anywhere in the world.

About Ebopiprant and PGF2a

ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F2a receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF2a is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin.

Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.

About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights (ex China).

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

All this fun with ATOM today, plus and I get to watch fellow boomer Steve Stricker show the young guns who's boss in Phoenix at the Waste Management Open. Life is good.

Where's the Like button in Ihub?